Cytonics Announces Successful Completion of Phase 1 Study for First Nine Patients in CYT-108 Clinical Trial
No adverse events reported; CYT-108 progressing as a potential disease-modifying therapy for osteoarthritis – Cytonics Corporation, a private biotechnology company developing cutting-edge biologic therapies for musculoskeletal conditions, today announced that the first nine patients in its Phase 1 clinical trial evaluating CYT-108 as a therapy for osteoarthritis have successfully completed the study. All patients received […]